Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.

Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.

The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

Retinal vascular obstruction is an eye disease that causes vision loss by clogging blood vessels that supply nutrition and oxygen to the retina. According to the Health Insurance Review and Assessment ...

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising ...

For women of reproductive age, pregnancy testing is another must before starting GLP-1 therapy. These medications are not recommended during pregnancy, making it essential to confirm pregnancy status ...

The top read ophthalmology articles of 2025 focused on a variety of topics within the field, including links between ...

ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.

BEFORE the clock strikes 12 on New Year’s Eve, you need to have nailed down your 2026 beauty resolutions. Whilst some ...

Over the past 60 days, estimates for ANI Pharmaceuticals’ 2025 adjusted EPS have increased from $7.29 to $7.56. Over the same ...

Lip fillers and blindness a rare but real risk Read ahead to know what experts say you must know before getting lip ...